{"filings":[{"id":918517,"accession_number":"0001193125-26-261770","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-06-08T20:15:38+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CFO Lowrance resigns due to health; Robert Lutz named CFO & COO; shareholders approve 2x share increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Lowrance resigns as CFO & CAO eff. July 15, 2026 due to health; receives severance and 12-month equity vesting acceleration.","Robert Lutz appointed CFO & COO eff. July 15, 2026; base salary $510,000; option for 70K shares, 35K RSUs.","Stockholders approved increasing authorized common shares from 300M to 600M at June 4 annual meeting.","Stockholders also approved amending 2024 Omnibus Incentive Plan to add 18.9M shares for issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101799,"accession_number":"0001193125-26-105099","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Savara signs lease for new HQ in Yardley, PA; 5-year term starting July 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 10,795 sq ft at 19 W. College Ave, Yardley, PA; term 7/1/2026 to 12/1/2031.","Base rent starts at ~$28,337/mo, 2% annual increases; aggregate base rent ~$1.78M over term.","Security deposit $28,337; additional costs for operating expenses, taxes, utilities.","Relocation of headquarters from Langhorne, PA to Yardley, PA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101798,"accession_number":"0001193125-26-023378","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.","First Post-Approval Tranche of $45M must be drawn within 120 days or by June 30, 2027.","Second $30M tranche available after first tranche drawn or expired, same deadline.","Financial covenant compliance dates extended: unrestricted cash to Apr 2027, revenue covenant to Sep 2027 if market cap low.","Lenders granted first-priority security interest in IP, converting to negative pledge if RTW Purchase Agreement terminated and $50M+ cash held."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101797,"accession_number":"0001193125-26-008301","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation posted on IR website and furnished as exhibit.","Reaffirms focus on rare respiratory diseases; no new clinical or financial data.","No changes to guidance, pipeline, or leadership disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118135,"accession_number":"0001193125-25-258629","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.","Underwriters granted 30-day option to purchase up to an additional 4.6M shares.","Proceeds to fund clinical development and regulatory approval of MOLBREEVI, plus commercialization and launch prep in US and EU.","Offering expected to close October 31, 2025, subject to customary conditions.","Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118134,"accession_number":"0001193125-25-256290","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.","Royalty rates tiered from 7.0% to 1.0% of U.S. net sales; 7.0% tier rises to 9.5% if prior-year sales fall short.","Royalty capped at $187.5M; company expects effective rate in low-single digits over life of agreement.","Securities class action filed Sept 8, 2025 alleging misstatements about MOLBREEVI regulatory filings; company intends to defend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134573,"accession_number":"0001193125-25-193507","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on IR website and furnished as Exhibit 99.1.","Presentation available at savarapharma.com/investors/events-presentations.","No specific financial or operational updates provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151437,"accession_number":"0001193125-25-137150","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Savara stockholders elect directors, ratify auditors, and approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with at least 118.7 million votes in favor each.","Ratification of RSM US LLP as auditor for 2025 received 151.3 million votes for, 28,827 against.","Advisory vote on executive compensation approved with 120.6 million for (97.3%).","Stockholders selected '1 year' as preferred frequency for future say-on-pay votes (122.9 million votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151436,"accession_number":"0001193125-25-126273","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested additional CMC data; RTF not due to safety or efficacy concerns.","Company plans Type A meeting within 30 days to align on next steps.","BLA for autoimmune PAP was submitted March 2025; resubmission targeted for Q4 2025.","Technology transfer for second-source drug substance manufacturer on track; three PPQ batches completed.","MOLBREEVI retains Fast Track, Breakthrough Therapy, and Orphan Drug status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170316,"accession_number":"0001193125-25-067658","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Savara terminates ATM equity offering agreement with Evercore, effective April 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delivered notice to Evercore on March 31, 2025 terminating the ATM Agreement under Section 12(b).","Agreement permitted sales of up to $100M in common stock; no shares sold since December 31, 2024.","Termination effective April 2, 2025; no penalties incurred by the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170315,"accession_number":"0001193125-25-064145","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.","Interest-only period of 36 months (extendable to 60 months upon FDA approval); floating rate of prime+1.45% (floor 6%+1.45%).","No warrants issued; loan matures April 1, 2030; collateral includes tangible assets (negative pledge on IP).","Milestone triggers: $80M available upon FDA approval (by end of 2025 if priority review), $20M upon revenue milestone post-2027, $70M at Hercules discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170314,"accession_number":"0001193125-25-011453","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Savara sets 2025 executive bonus targets; CEO bonus $330k, other execs $165k-$200k","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Matthew Pauls target bonus $330,000 (50% of base salary).","CFO Dave Lowrance and COO Rob Lutz each target $188,400 (40% of base).","CMO Raymond Pratt target $200,400; CBO Anne Erickson $165,080; CCO Braden Parker $180,000.","CEO bonus based 100% on corporate goals; other execs 75% corporate, 25% individual measures.","Actual payouts subject to board discretion and performance goal achievement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170313,"accession_number":"0001193125-25-005034","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation updated and posted on IR website on January 13, 2025.","Presentation titled 'Developing New Therapies for Rare Respiratory Diseases'.","No specific financial data or material events provided in the filing.","Presentation furnished as Exhibit 99.1 but contains no new material substantive disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220426,"accession_number":"0001193125-24-171564","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Savara prices $100M common stock offering at $3.81/sh, 26.2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$100M from 26,246,720 shares at $3.81 per share.","Offering expected to close July 1, 2024; subject to customary conditions.","Investors include Bain Capital Life Sciences, Farallon, Frazier, Wellington, Nantahala, TCGX, First Light.","Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers.","Offered under existing effective shelf registration statement (File No. 333-279274)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220425,"accession_number":"0001193125-24-168501","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).","Statistically significant improvement sustained at Week 48: DLCO 6.90% (p=0.0008).","SGRQ Total Score statistically significant at Week 24 (-6.59 points, p=0.0072); SGRQ Activity and exercise capacity nominally significant.","Well-tolerated; no drug-related discontinuations; 97% completed double-blind; all patients elected 96-week open-label.","Company plans to complete BLA submission to FDA in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220422,"accession_number":"0001193125-24-158429","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K/A","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Savara stockholders approve 2024 Omnibus Incentive Plan adding 11.7M new shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved 2024 Omnibus Incentive Plan at June 6, 2024 annual meeting.","Plan reserve includes 11.7M new shares plus any shares remaining under prior plan and forfeited awards.","Plan authorizes grants of options, SARs, restricted stock, RSUs, and other awards to eligible individuals.","Key terms: exercise price at least 100% FMV, max term 10 years, Non-Employee Director annual limit $1M total value.","Outstanding prior 2015 plan awards continue; no new grants under prior plan after effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220424,"accession_number":"0001193125-24-157366","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Savara shareholders approve officer exculpation charter amendment and 2024 omnibus incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to certificate of incorporation allowing officer exculpation under Delaware law approved (88.6M for, 14.1M against).","2024 Omnibus Incentive Plan approved with 91.3M votes for, 11.4M against.","All six director nominees elected; Matthew Pauls received 101.5M votes for.","Ratification of RSM US LLP as auditor passed with 120.4M votes for, 385K against.","Advisory vote on executive compensation approved with 98.3M votes for, 4.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220423,"accession_number":"0001193125-24-094640","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["1.01","8.01","5.02"],"status":"ready","headline":"Savara director Dr. Ricky Sun not to stand for reelection; Bain waives board designation right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Ricky Sun notified Board on April 10, 2024 of intention not to stand for reelection at 2024 Annual Meeting; will serve until then.","Sun's decision not related to any dispute or disagreement with Savara on operations, policies, or practices.","Bain Capital Life Sciences permanently waived its right under 2019 Purchase Agreement to designate a Board member.","Designation right was triggered when Bain held at least 50% of purchased shares or 5% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240065,"accession_number":"0001193125-24-038108","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Savara enters master services agreement with Fujifilm for molgramostim manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers development and manufacturing services for molgramostim active pharmaceutical ingredient.","Scope of Work #03 executed for Process Performance Qualification manufacturing campaign.","Either party may terminate with three months' notice if no scope-of-work activities are in process.","Termination also allowed for material uncured breach or unforeseen technical issues by Fujifilm.","Includes standard provisions on confidentiality, intellectual property, liability, and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240064,"accession_number":"0001193125-24-015391","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Savara approves 2024 target bonuses: CEO $310k (50%), CMO $194.6k (40%), CFO $182k (40%), COO $181.8k (40%)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Matthew Pauls 2024 target bonus set at $310,000 (50% of base salary), fully tied to corporate performance.","CMO Raymond Pratt target bonus $194,580 (40% of base), 75% corporate + 25% individual.","CFO Dave Lowrance target bonus $182,025 (40% of base), same split.","COO Rob Lutz target bonus $181,792 (40% of base), same split.","Actual awards may vary based on performance goal achievement; Board retains discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240063,"accession_number":"0001193125-24-002889","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation with no new material information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation furnished as Exhibit 99.1, available on Savara's website.","Presentation focuses on rare respiratory disease pipeline; no specific financial or clinical updates provided.","No guidance, trial results, or material events disclosed in the filing.","Presentation is a routine review of company strategy and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274919,"accession_number":"0001193125-23-186640","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Savara prices $80M underwritten offering of common stock and pre-funded warrants at $3.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 21M common shares at $3.00/share and 5.67M pre-funded warrants at $2.999/warrant for $80M gross proceeds.","Expected close July 17, 2023; Jefferies and Piper Sandler are joint book-runners.","New investors include TCGX, Frazier Life Sciences, Janus Henderson; existing investors Bain, NEA, Adage, Venrock participating.","Securities offered under effective shelf registration statement (File No. 333-257709).","Proceeds to fund clinical development and working capital (implied for clinical-stage rare respiratory disease company)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292279,"accession_number":"0001193125-23-164012","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Savara stockholders elect all director nominees, approve 3M share increase at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with >66M votes for each; Nevan Elam received 66.7M for, 15.7M against.","Shareholders approved 3,000,000 share increase to 2015 Plan with 81.9M for, 0.5M against (94.5% support).","RSM US LLP ratified as auditor for FY2023 with 91.96M for, 0.43M against (99.5% support).","Advisory vote on named executive compensation passed with 79.1M for, 3.3M against (96.0% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292278,"accession_number":"0001193125-23-163526","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on IR page and furnished as Exhibit 99.1.","Presentation covers Savara's rare respiratory disease pipeline, no specific financial/operational updates provided.","No changes to guidance, pipeline status, or financial outlook disclosed in the filing.","Savara undertakes no obligation to update the presentation except through normal channels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312990,"accession_number":"0001193125-23-085762","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Savara amends bylaws to update stockholder proposal and director nomination procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added updated procedures for stockholder proposals and director nominations, including additional information requirements.","Requires nominating stockholders to comply with Rule 14a-19 universal proxy rules and use a proxy card color other than white.","Revised director removal provision: directors may be removed with or without cause by majority vote.","Added emergency bylaw provision for board quorum during emergencies; updated electronic transmission notice provisions.","Amendments also reflect name change from Mast Therapeutics to Savara Inc. and conform to recent DGCL changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312989,"accession_number":"0001193125-23-067583","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Savara says SVB closure exposure immaterial; >99% of cash held elsewhere","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Savara discloses its exposure to Silicon Valley Bank closure is immaterial.","Over 99% of Savara's cash and securities are held at a different large custodial bank.","The unaffected custodian is not impacted by the SVB closure.","No other material financial details provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312988,"accession_number":"0001193125-23-058291","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Savara expands Langhorne office lease, relocates HQ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended lease adds 3,970 sq ft to current 2,465 sq ft office in Langhorne, PA.","Monthly rent increases from ~$5,850 to ~$14,200 (Jul 2023-Jun 2024), then to $14,500 and $14,700.","Lease term extended to June 30, 2026; Savara plans to relocate headquarters to this site.","Amendment effective Feb 28, 2023; full lease terms to be filed with Q1 2023 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312987,"accession_number":"0001193125-23-037363","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Savara appoints Robert Lutz as COO with $437K salary, $115K signing bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lutz, former CFO/COO of iBio and Strongbridge, joins Savara as COO effective Feb 13, 2023.","Base salary of $437,000; annual bonus target of 40% of base salary; signing bonus of $115,000.","Subject to Board approval, receives option for 350,000 shares vesting over 4 years and 140,000 RSUs vesting in 2 years.","Severance includes 12 months salary plus prorated bonus outside CIC; 18 months plus 100% bonus within CIC period.","Vesting acceleration on termination: 12 months of unvested options vest outside CIC; full acceleration within CIC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331506,"accession_number":"0001193125-22-305901","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Savara appoints Dave Lowrance as CFO & CAO; enters amended CEO/CFO employment agreements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Matt Pauls amended agreement: $595k base salary, 50% target bonus, enhanced severance.","CFO Dave Lowrance promoted to CFO & CAO; new agreement: $437,561 base, 40% target bonus.","2023 bonus targets: CEO $297,500, CMO $188,000, CFO & CAO $175,024.","Severance includes COBRA reimbursements up to 18 months (24 months within Change of Control).","Effective date December 13, 2022; agreements supersede prior versions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349036,"accession_number":"0001193125-22-230624","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Savara CMO Dr. Badrul Chowdhury resigns effective Sept. 9, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Badrul Chowdhury resigned as Chief Medical Officer, effective September 9, 2022.","Resignation not due to any disagreement with Savara's operations, policies, or practices.","No successor named; search for new CMO expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365865,"accession_number":"0001193125-22-166845","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Savara shareholders elect 8 directors, approve equity plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected; Matthew Pauls led with 65.3M votes for, 379K against.","Amendment to 2015 Omnibus Incentive Plan approved, increasing shares by 4,000,000 (64.9M for, 967K against).","Ratification of RSM US LLP as auditor for FY2022 passed with 76.5M for, 2.6M against.","Advisory vote on named executive compensation approved (64.8M for, 840K against).","Meeting held June 2, 2022; all proposals passed with broker non-votes noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365864,"accession_number":"0001193125-22-114263","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Savara enters $26.5M term loan facility with Silicon Valley Bank; refinances prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended and restated loan agreement provides $26.5M term loan, refinancing all outstanding obligations under prior facility.","Interest-only period through April 2026; if cash >1.75x outstanding, extends to maturity in April 2027.","Floating interest rate: greater of 3% or prime minus 0.5%; final payment of 2.75% of principal.","Secured by substantially all assets except intellectual property; prepayment fee 4.25% in first year, 1% in second, none thereafter.","Cash covenant: if balance falls below $40M, must maintain 6 months operating expenses and 1.2x loan principal (1.75x in final year if extended)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385379,"accession_number":"0001193125-22-008657","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2022-01-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Savara approves 2022 target bonuses: CEO $290K (50% base), CMO $219.5K (40%), CFO $166.7K (40%)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pauls target bonus $290,000 (50% of base); 100% corporate performance measures.","CMO Chowdhury target bonus $219,544 (40% of base); 75% corporate, 25% individual goals.","CFO Lowrance target bonus $166,690 (40% of base); 75% corporate, 25% individual goals.","Actual payout may vary based on achievement of performance goals; Board retains discretion.","Compensation Committee recommended; Board approved on January 13, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385378,"accession_number":"0001193125-22-005111","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no specific financial or clinical data disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation furnished as Exhibit 99.1, available on Savara's IR website.","Presentation title indicates continued focus on rare respiratory diseases.","No material changes or new quantitative information provided in the 8-K or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422179,"accession_number":"0001193125-21-209282","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2021-07-07T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Savara enters $60M at-the-market equity offering program with Evercore","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Savara signs Sales Agreement with Evercore to sell up to $60M of common stock in ATM offerings.","Prior $75M ATM agreement with H.C. Wainwright terminated on July 2, 2021.","Evercore receives customary commission; Savara has no obligation to sell any shares.","Offers will be made under Savara's existing S-3 shelf registration statement (File No. 333-257709)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}